Does plasminogen activator inhibitor-1 drive lymphangiogenesis?
The purpose of this study is to explore the function of plasminogen activator inhibitor-1 (PAI-1) during pathological lymphangiogenesis. PAI-1, the main physiological inhibitor of plasminogen activators is involved in pathological angiogenesis at least by controlling extracellular proteolysis and by...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2010-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC2836381?pdf=render |
| _version_ | 1811226867717373952 |
|---|---|
| author | Françoise Bruyère Laurence Melen-Lamalle Silvia Blacher Benoît Detry Anne Masset Julie Lecomte Vincent Lambert Catherine Maillard Gunilla Høyer-Hansen Leif R Lund Jean-Michel Foidart Agnès Noël |
| author_facet | Françoise Bruyère Laurence Melen-Lamalle Silvia Blacher Benoît Detry Anne Masset Julie Lecomte Vincent Lambert Catherine Maillard Gunilla Høyer-Hansen Leif R Lund Jean-Michel Foidart Agnès Noël |
| author_sort | Françoise Bruyère |
| collection | DOAJ |
| description | The purpose of this study is to explore the function of plasminogen activator inhibitor-1 (PAI-1) during pathological lymphangiogenesis. PAI-1, the main physiological inhibitor of plasminogen activators is involved in pathological angiogenesis at least by controlling extracellular proteolysis and by regulating endothelial cell survival and migration. Protease system's role in lymphangiogenesis is unknown yet. Thus, based on its important pro-angiogenic effect, we hypothesized that PAI-1 may regulate lymphangiogenesis associated at least with metastatic dissemination of cancer cells. To address this issue, we studied the impact of PAI-1 deficiency in various murine models of tumoral lymphangiogenesis. Wild-type PAI-1 proficient mice were used as controls. We provide for the first time evidence that PAI-1 is dispensable for tumoral lymphangiogenesis associated with breast cancers either induced by mammary carcinoma cell injection or spontaneously appearing in transgenic mice expressing the polyomavirus middle T antigen (PymT) under the control of a mouse mammary tumor virus long-terminal repeat promoter (MMTV-LTR). We also investigated inflammation-related lymphatic vessel recruitment by using two inflammatory models. PAI-1 deficiency did neither affect the development of lymphangioma nor burn-induced corneal lymphangiogenesis. These novel data suggest that vascular remodelling associated with lymphangiogenesis and angiogenesis involve different molecular determinants. PAI-1 does not appear as a potential therapeutic target to counteract pathological lymphangiogenesis. |
| first_indexed | 2024-04-12T09:32:02Z |
| format | Article |
| id | doaj.art-15c40bb61a56458b857f844d8f41417c |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T09:32:02Z |
| publishDate | 2010-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-15c40bb61a56458b857f844d8f41417c2022-12-22T03:38:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-01-0153e965310.1371/journal.pone.0009653Does plasminogen activator inhibitor-1 drive lymphangiogenesis?Françoise BruyèreLaurence Melen-LamalleSilvia BlacherBenoît DetryAnne MassetJulie LecomteVincent LambertCatherine MaillardGunilla Høyer-HansenLeif R LundJean-Michel FoidartAgnès NoëlThe purpose of this study is to explore the function of plasminogen activator inhibitor-1 (PAI-1) during pathological lymphangiogenesis. PAI-1, the main physiological inhibitor of plasminogen activators is involved in pathological angiogenesis at least by controlling extracellular proteolysis and by regulating endothelial cell survival and migration. Protease system's role in lymphangiogenesis is unknown yet. Thus, based on its important pro-angiogenic effect, we hypothesized that PAI-1 may regulate lymphangiogenesis associated at least with metastatic dissemination of cancer cells. To address this issue, we studied the impact of PAI-1 deficiency in various murine models of tumoral lymphangiogenesis. Wild-type PAI-1 proficient mice were used as controls. We provide for the first time evidence that PAI-1 is dispensable for tumoral lymphangiogenesis associated with breast cancers either induced by mammary carcinoma cell injection or spontaneously appearing in transgenic mice expressing the polyomavirus middle T antigen (PymT) under the control of a mouse mammary tumor virus long-terminal repeat promoter (MMTV-LTR). We also investigated inflammation-related lymphatic vessel recruitment by using two inflammatory models. PAI-1 deficiency did neither affect the development of lymphangioma nor burn-induced corneal lymphangiogenesis. These novel data suggest that vascular remodelling associated with lymphangiogenesis and angiogenesis involve different molecular determinants. PAI-1 does not appear as a potential therapeutic target to counteract pathological lymphangiogenesis.http://europepmc.org/articles/PMC2836381?pdf=render |
| spellingShingle | Françoise Bruyère Laurence Melen-Lamalle Silvia Blacher Benoît Detry Anne Masset Julie Lecomte Vincent Lambert Catherine Maillard Gunilla Høyer-Hansen Leif R Lund Jean-Michel Foidart Agnès Noël Does plasminogen activator inhibitor-1 drive lymphangiogenesis? PLoS ONE |
| title | Does plasminogen activator inhibitor-1 drive lymphangiogenesis? |
| title_full | Does plasminogen activator inhibitor-1 drive lymphangiogenesis? |
| title_fullStr | Does plasminogen activator inhibitor-1 drive lymphangiogenesis? |
| title_full_unstemmed | Does plasminogen activator inhibitor-1 drive lymphangiogenesis? |
| title_short | Does plasminogen activator inhibitor-1 drive lymphangiogenesis? |
| title_sort | does plasminogen activator inhibitor 1 drive lymphangiogenesis |
| url | http://europepmc.org/articles/PMC2836381?pdf=render |
| work_keys_str_mv | AT francoisebruyere doesplasminogenactivatorinhibitor1drivelymphangiogenesis AT laurencemelenlamalle doesplasminogenactivatorinhibitor1drivelymphangiogenesis AT silviablacher doesplasminogenactivatorinhibitor1drivelymphangiogenesis AT benoitdetry doesplasminogenactivatorinhibitor1drivelymphangiogenesis AT annemasset doesplasminogenactivatorinhibitor1drivelymphangiogenesis AT julielecomte doesplasminogenactivatorinhibitor1drivelymphangiogenesis AT vincentlambert doesplasminogenactivatorinhibitor1drivelymphangiogenesis AT catherinemaillard doesplasminogenactivatorinhibitor1drivelymphangiogenesis AT gunillahøyerhansen doesplasminogenactivatorinhibitor1drivelymphangiogenesis AT leifrlund doesplasminogenactivatorinhibitor1drivelymphangiogenesis AT jeanmichelfoidart doesplasminogenactivatorinhibitor1drivelymphangiogenesis AT agnesnoel doesplasminogenactivatorinhibitor1drivelymphangiogenesis |